“…For structural analysis, we used methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA, MRC Holland, Amsterdam, Netherlands) analysis for each imprinted region (ME030 for 11p15.5, ME028 for 15q11.3–5, ME031 for 20q13) and/or aCGH analysis using custom built array (Design ID 080262, Agilent Technologies, Palo Alto, CA) and/or genome-wide comparative genomic hybridization and single-nucleotide polymorphism array (catalog number G4890A, Agilent Technologies, Palo Alto, CA), according to the manufacturer’s instructions. For patients with abnormal methylation levels of the DMRs related to known IDs other than H19 LOM and UPD(7)mat, but not structural abnormalities, we carried out microsatellite analysis for chromosomes 6 ( 16 ), 14 ( 8 ), 15 ( 17 ), 16 ( 10 ), and 20 ( 11 ) using patients’ and their parental genomic DNA samples. If patients had aberrant methylated DMR(s) other than their disease-related DMR(s), we considered these patients as having multilocus imprinting disturbance (MLID).…”